GT Biopharma, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
GTBP$4.42-2.6%Stored close · as of Nov 6, 2026
Contents
Item 1. Financial Statements
| Condensed Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025 | 3 | ||
| Condensed Statements of Operations for the three months ended March 31, 2026 and 2025 (Unaudited) | 4 | ||
| Condensed Statements of Stockholders’ Equity (Deficit) for the three months ended March 31, 2026 and 2025 (Unaudited) | 5 | ||
| Condensed Statements of Cash Flows for the three months ended March 31, 2026 and 2025 (Unaudited) | 6 | ||
| Notes to Unaudited Condensed Financial Statements | 7 | ||
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 18 | |
|---|---|---|---|
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 25 | |
| Item 4. | Controls and Procedures | 25 | |
| PART II OTHER INFORMATION | |||
| Item 1. | Legal Proceedings | 27 | |
| Item 1A. | Risk Factors | 28 | |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 28 | |
| Item 3. | Defaults Upon Senior Securities | 28 | |
| Item 4. | Mine Safety Disclosures | 28 | |
| Item 5. | Other Information | 28 | |
| Item 6. | Exhibits | 29 | |
| SIGNATURES | 30 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.